top of page
  • bill3766

FDA Approves New Drug for Deadly Lung Cancer

The FDA has approved tarlatamab (Imdelltra) for treating advanced extensive-stage small cell lung cancer, offering hope to patients who have exhausted all other treatment options. Developed by Amgen, the drug showed promising results in a trial, tripling patients' life expectancy to a median survival of 14 months, though not all patients responded. Despite its effectiveness, tarlatamab carries a serious side effect called cytokine release syndrome. Click here for article.

  • Tarlatamab (Imdelltra) receives FDA approval for treating advanced extensive-stage small cell lung cancer.

  • Developed by Amgen, the drug triples patients' life expectancy in a trial, with a median survival of 14 months, although not all patients respond to it.

  • Laurie Fenton Ambrose of GO2 for Lung Cancer praises the approval as a significant advancement after decades of minimal progress in treating small cell lung cancer.

  • Tarlatamab comes with a serious side effect called cytokine release syndrome, which can cause symptoms like rash, rapid heartbeat, and low blood pressure.





0 views0 comments

Comentários


bottom of page